{"filing":{"accession_number":"0001493152-26-027210","cik":"0000946644","ticker":"AIM","company_name":"AIM ImmunoTech Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226027210/form8-k.htm"},"events":[{"id":6915,"run_id":6061,"accession_number":"0001493152-26-027210","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The filing discloses release of an on-demand video presentation and investor materials detailing pre-clinical findings on Ampligen® (rintatolimod) as a potential prophylactic/early-onset antiviral treatment for Ebola virus disease. While this represents material disclosure of clinical/research developments for the company's lead drug candidate, it does not fit cleanly into standard event categories (not earnings, M\u0026A, executive changes, impairment, litigation, or cybersecurity). The forward-looking nature and clinical development focus suggest investor-material information about the company's pipeline, warranting classification as other_material rather than a more specific category.","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":4466,"accession_number":"0001493152-26-027210","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses release of an on-demand video presentation and investor materials detailing pre-clinical findings on Ampligen® (rintatolimod) as a potential prophylactic/early-onset antiviral treatment for Ebola virus disease. While this represents material disclosure of clinical/research developments for the company's lead drug candidate, it does not fit cleanly into standard event categories (not earnings, M\u0026A, executive changes, impairment, litigation, or cybersecurity). The forward-looking nature and clinical development focus suggest investor-material information about the company's pipeline, warranting classification as other_material rather than a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:21:17.709738+00:00","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-06-04"}]}